CD36 and diabetes mellitus: We postulated that if increased S-acylation was one of the drivers for metabolic dysfunction, then strategies that decrease CD36 S-acylation should be beneficial in diabetes, and, to the contrary, strategies that increased CD36 S-acylation should be deleterious in control hearts by recapitulating the diabetic phenotype.